Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating
patients with Crohn’s disease (CD) and ulcerative colitis (UC). We aimed to determine whether …

Background Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's
disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still …

Background and aims: Elicitation of an innate immune response to bacterial products is
mediated through pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs) and …

BACKGROUND: Approximately 85% of nasal polyps (NPs) in white subjects are characterized
by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival…

Background and aims: This observational study assessed the long-term clinical benefit of
infliximab (IFX) in 614 consecutive patients with Crohn’s disease (CD) from a single centre …

Background Antimicrobial peptides (AMPs) protect the host intestinal mucosa against
microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD…

Rationale: T-bet (TBX21 or T-box 21) is a critical regulator of T-helper 1 lineage commitment
and IFN-γ production. Knockout mice lacking T-bet develop airway hyperresponsiveness (…

BACKGROUND: Nasal polyps often are associated with asthma. The phenotype of these
patients is unknown. OBJECTIVE: To identify the mucosal factors associated with asthma …

Background and aims: Infliximab is an effective treatment for ulcerative colitis with over 60%
of patients responding to treatment and up to 30% reaching remission. The mechanism of …

BACKGROUND & AIMS:: Infliximab therapy is an effective approach to treating Crohn’s
disease. Development of antinuclear antibodies has been described in patients treated, but the …